ReviewmBio2025
mGem: Noncanonical nucleic acid structures-powerful but neglected antiviral targets.
Review in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Modulating G-quadruplexes for therapeutic intervention: Structural diversity, stability, and emerging nucleic-acid-based strategies.Molecular therapy. Nucleic acids · 2026Review
- Characterization of Z-DNA dynamics across the tree of life.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This perspective highlights the emerging significance of noncanonical nucleic acid structures-such as G-quadruplexes, Z-DNA/Z-RNA, and cruciforms-in viral genomes. Once considered structural oddities, these motifs are now recognized as critical regulators of viral replication, transcription, genome stability, and host-pathogen interactions. Despite mounting evidence of their functional relevance and therapeutic potential, these structures remain largely overlooked in virology and antiviral drug development. Their unique conformations offer highly specific molecular targets, with several small molecules already demonstrating the ability to modulate viral gene expression by stabilizing or destabilizing these motifs. The persistent underestimation of non-B DNA/RNA structures represents a missed opportunity in the fight against viral diseases. By synthesizing recent discoveries and emphasizing their biological and pharmacological promise, we aim to elevate awareness and catalyze interdisciplinary research. Harnessing the structural diversity of viral genomes could unlock novel antiviral strategies with high specificity and minimal off-target effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.